Abstract
Keywords
Apoptosis Chemotherapeutic drugs Noscapine Paclitaxel Prostate cancer
Introduction
Prostate cancer is the most common malignancy and the second leading cause of cancer- related death of men in the United States (1). The treatment options for patients include surgery, chemotherapy, radiation, and hormonal therapy, and combinations of some of these treatments. One of the most common chemotherapeutic drugs used for the treatment of prostate cancer are the taxanes (paclitaxel, taxol) (2, 3). Paclitaxel was derived originally from the Pacific Yew tree Taxus brevifolia (4) and it is current treatment of head and neck (5) , breast, ovarian, lung, prostate (2, 6), and gastric (7) cancers.
Paclitaxel is generally accepted to induce cell cycle arrest and apoptosis in most types of cancer cells (8, 9). Paclitaxel interferes with microtubule assembly by binding and stabilizing β-tubulin in the G2/M phase of the cell cycle (10, 11). However, clinical utility of paclitaxel has been limited due to numerous serious side effects (8, 21) and drug resistance (13). Noscapine is an antitussive opium alkaloid that lacks analgesic, euphoric, sedative, and respiratory depressant properties (14). Noscapine binds to tubulin and alters its conformation and assembly properties, interferes with microtubule dynamics both in-vivo and in-vitro, arrests a variety of mammalian cells in mitosis and targets them for apoptosis (14, 15, 16). However, noscapine is unable to compete with paclitaxel for binding to tubulin, suggesting that noscapine binds to a site other than the paclitaxel-binding site (17). Noscapine has showed antitumor activity against a variety of cancer: breast (14), melanoma (15), ovarian (17), gliobastoma (18), lymphoma (19), human myelogenous leukemia (20), and lung both in-vitro and in-vivo (21) while has not exhibited severe side effects that are commonly seen with many chemotherapeutic agents. Combination treatment with multiple therapeutic agents has been used to enhance the efficacy of treatment in controlling cancer cells (22, 23). In the present study, we investigated the synergistic anticancer activity of paclitaxel and noscapine against LNCaP and PC-3 human prostate cancer cell lines.
Experimental
Cell lines & drugs
Human prostate cancer cell lines LNCaP (androgen receptor-positive; androgen-dependent) and PC-3 (androgen receptor-negative; androgen-resistant) were obtained from the National Cell bank of Iran (NCBI) and cultured in RPMI 1640 medium supplemented by 10% fetal bovine serum (FBS), penicillin G (100 IU/mL) and streptomycin (100 µg/mL). The cells were maintained at 37 °C in a humidified atmosphere in the presence of 5% CO2. All studies were done with cells at 70 to 80% confluence. Paclitaxel and noscapine were purchased from Sigma-Aldrich Co., USA .The drugs were dissolved in dimethyl sulfoxide (DMSO) and stored at −20 °C as a stock solution. The final concentration of DMSO in culture medium was 0.1% which was always nontoxic.
Cell treatment
LNCaP and PC-3 cell lines were seeded in 96-well plates, at a density of 2×104 cells/well. After 24 h the cells were treated with various dilutions of paclitaxel (10, 25, 50 and 100 nM) or noscapine (10, 25, 50 and 100 μM) from stock solutions in DMSO for 24, 48, and 72 h.
In another set of experiments, the cells were treated with 50 nM Paclitaxel in combination with different concentrations of noscapine (10, 25, 50 and 100 μM) for 48 h, and untreated cells were served as control.
Cell viability assay
LNCaP and PC-3 cells viability was assessed by Cell proliferation kit I (MTT[3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide]) Roche, GmbH, Germany) according to the manufacturer’s protocol. Briefly, 2×104 cells were plated in 96-well plates and exposed to serial concentrations of paclitaxel (10, 25, 50 and 100 nM) or noscapine (10, 25, 50 and 100 μM) for 24, 48, and 72 h. A separate study was done to find out the growth inhibitory effects of various concentration of noscapine (10, 25, 50 and 100 μM) on IC50 value (50 nM) of paclitaxel on LNCaP and PC-3 cells after 48 h. Each experiment was carried out at least in triplicate. All experiments were done at least in triplicate wells and the assays were repeated independently three times.
The viability assay is based on the cleavage of yellow tetrazolium salt to purple formazan crystals by metabolic active cells (24). After the treatment periods, 10 µL of yellow MTT solution (final concentration 0.5 mg/mL) was added to each well and incbated at 37 °C in 5% CO2 for 4 h the purple formazan salt crystals were dissolved by adding solubilization solution. The absorbance of the samples was measured at 570 nm using a microplate (ELISA) reader (Stat fax 2100, USA). Cell viability calculated as the ratio of absorbance of treated groups divided into the absorbance of control group, multiplied by 100 to achieve a viability percent.
Cell death assay
LNCaP and PC-3 cells were treated with 50 nM paclitaxel, or 50 μM noscapine or combination for 48 h, and untreated cells were used as control. Treatments-induced apoptosis was carried by AO/EB (acridine orange/ ethidium bromide) double staining assay as previously described (25). Acridine orange is taken up by both viable and nonviable cells and emits green fluorescence if interrelated into double stranded nucleic acid (DNA). Ethidium bromide is taken up only by nonviable cells and emits red fluorescence by intercalation into DNA. We distinguished four types of cells according to the fluorescence emission and the morphological aspect of chromatin condensation in the stained nuclei.
Viable cells have uniform bright green nuclei with organized structure. Early apoptotic cells (which still have intact membranes but have started to undergo DNA cleavage) have green nuclei, but perinuclear chromatin condensation is visible as bright green patches or fragments. Late apoptotic cells have orange to red nuclei with condensed or fragmented chromatin. Necrotic cells have a uniformly orange to red nuclei with condensed structure. The amount of 100 µL of dye mixture (100 µg/mL AO and 100 µg/mL EB in PBS) was added to cells in 96-well plate. The cells were viewed under a fluorescence microscope (Olympus, IX71). A minimum of 200 cells were counted in each sample.
RNA isolation and RT-PCR (reverse transcription polymerase chain reaction)
LNCaP and PC-3 cells were treated with 50 nM paclitaxel or 50 μM noscapine and combination for 48. Untreated cells were used as control. The mRNA expression of Bax and Bcl-2 was determined by Relative RT-PCR. The cells were harvested by trypsinization, washed three times, and pelleted by centrifugation. Total RNA was extracted using RNA purification kit (Jena Bioscience, GmbH, Germany). cDNA synthesis was performed by 0.5 μg of total RNA with AccuPower® RocketScriptTM RT PreMix kit (Bioneer, Korea) with oligo dT and random hexamer primers in a volume of 20 µL. PCR was performed using oligonucleotide specific primers for Bax, Bcl-2, AR, PSA.GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was used as an internal control. Amplification was performed by using the following primers:
Bax forward primer 5´-GGGGACGAACTGGACAGTAA-3´, Reverse primer 5´-CAGTTGAAGTTGCCGTCAGA-3´ (GenBank accession no. NM_004324.3);
Bcl-2 forward primer 5´-ATGTGTGTGGAGAGCGTCAA-3´, reverse primer 5´ -ACAGTTCCACAAAGGCATCC-3´(GenBank accession no. NM_000633.2 (;
AR forward primer 5´- CCTGGCTTCCGCAACTTACAC-3´, reverse primer 5´- GGACTTGTGCATGCGGTACTCA-3´(GenBank accession no. NM_001011645.2);
PSA forward primer 5´- ACCAGAGGAGTTCTTGACCCCAAA-3´, reverse primer 5´- CCCCAGAATCACCCGAGCAG-3´ (GenBank accession no. NM_001648.2).
GAPDH forward primer 5´-CAGCCTCAAGATCATCAGCA-3´, reverse primer 5´- TGTGGTCATGAGTCCTTCCA-3´ (GenBank accession no. NM_002046.4).
PCR reactions were carried out in total volumes of 20 µL using PCR PreMix kit (Bioneer, Korea) according to the manufacturer’s instructions with an AG PCR system (Eppendorf, Hamburg, Germany). The cycling conditions were as follows: initial denaturation at 94 ºC for 10 min, followed by 30 cycles of denaturation at 94 ºC for 1 min, 59 ºC (GAPDH), 60 ºC (Bax and Bcl-2), 66 ºC (PSA), 67 ºC (AR) annealing for 1 min and extension at 72 ºC for 1 min, with a final extension at 72 ºC for 10 min, following a 4 °C incubation for 10 min.
Relative RT-PCR analysis
The mRNA expression of Bax, Bcl-2, PSA, and AR was quantified against the housekeeping gene (GAPDH). The PCR products were visualized by electrophoresis on 1.5% agarose gels followed by ethidium bromide staining (1 µg/mL) and photographed on an ultraviolet transilluminator (UVIdoc; Uvitec, Cambridge, UK). Gel images were analyzed using the Uvitec program. Relative RT–PCR values were presented as a ratio of the density of bands divided by density of GAPDH bands. Each experiment was repeated at least three times.
Statistical analysis
Results were obtained through at least three separate experiments. One-way ANOVA test was performed to determine the significance of differences among groups using SPSS statistical software (version 16.0 SPSS Inc.). All data are shown as means ± SEM. and values of P<0.05 were considered significant.
Results
Effects of paclitaxel and noscapine on LNCaP and PC-3 cells viability
The effects of paclitaxel and noscapine, alone or in combination on cell viability, was evaluated by MTT assay. The results showed that single and combination treatments of both paclitaxel and noscapine significantly decreased the viability of both LNCaP and PC-3 cells in a dose and time-dependent manner compared to control cells (Figures 1A and B). Differences in sensitivity between two cell types were observed, so that androgen-sensitive LNCaP cells were more sensitive than the hormone-refractory PC-3 cells to both single and combination treatments (P<0.05).
In LNCaP cells, paclitaxel induced dose- and time-dependent effect on the viability of this cell line (P<0.05). After 24, 48 and 72 h with increasing paclitaxel concentration from 10 to 100 nM, cell viability of LNCaP cells was decreased from 94.2 ± 1.78 to 55.8 ± 6.3, 73.59 ± 0.1 to 42.13 ± 1.57 and 39.4 ± 2.77 to 16.02 ± 0.67% respectively. In contrast, in PC-3, cell viability was decreased from 96.55 ± 1.35 to 59.26 ± 1.26, 82.94 ± 5.24 to 49.2 ± 5.4 and 64.84 ± 2.36 to 39.62 ± 1.6% respectively in response to 24, 48, and 72 h treatments with 10 to 100 nM of paclitaxel (P<0.05).
On the other hand, After 24, 48, and 72 h with increasing noscapine concentration from 10 to 100 µM, cell viability of LNCaP cells was decreased from 96.11 ± 0.62 to 70.7 ± 1.85, 77.86 ± 0.14 to 46.13 ± 1.17, and 40.4 ± 1.6 to 17.78 ± 0.82% respectively (P<0.05) (Figure 1A). In contrast, cell viability was decreased from 97.93 ± 0.3 to 77.6 ± 1, 89.1 ± 2.1 to 51.31 ± 3.2, and 80.84 ± 0.1 to 40.18 ± 7.2% respectively in PC-3 cells in response to 24, 48, and 72 h treatments with 10 to 100 µM of concentration of noscapine (P<0.05).
Paclitaxel and noscapine showed IC50 of 50 nM and 50 µM against LNCaP cells respectively after 48 h P<0.05). Therefore, in other set of experiments, 50 nM paclitaxel was used in the combination treatment with various concentrations of noscapine (10, 25, 50 and 100 µM) and cell viability was evaluated after 48 h. Combination of both agents further decreased the cell viability of LNCaP and PC-3 cells. In these treatments, cell viability percentages in LNCaP cells in 10, 25, 50, and 100 µM noscapine in combination with 50 nM of paclitaxel were 42.32 ± 1.39, 34.26 ± 2.49, 31.29 ± 1.5, and 28.1 ± 3.1, and it were 55 ± 0.5, 47 ± 1.02, 40.62 ± 1.77, and 33.38 ± 1.94% of in PC-3 cells respectively (P<0.05) (Figure 1B).
Data showed that each cell type was significantly more sensitive to the combination treatment than to control cells and single treatments indicating a strong synergism between the two drugs. The inhibitory effect on cell viability also was more in LNCaP cells than in PC-3 cells (Figure1 A and B).
Induction of apoptosis in LNCaP and PC-3 cells
LNCaP and PC-3 cells undergoing apoptosis following treatment with noscapine (50 µM), paclitaxel (50 nM), and combination compared to untreated cells after 48 h. Apoptosis was demonstrated by staining nuclei with AO/EB staining (Figure 2A). The percentages of treatment-induced apoptosis in LNCaP cells were higher (P<0.05) than apoptosis in PC-3 cells in both single and combination treatments. Apoptotic percentages of LNCaP cells were 39.6 ± 3.54 in 50 µM noscapine and 44.5 ± 3.51% in 50 nM paclitaxel (P<0.001). While, apoptotic percentages of PC-3 cells were 28.04 ± 0.04 in 50 µM noscapine and 31.7 ± 1.2% in 50 nM paclitaxel (Figure 2B) (P<0.05).
Combination treatments of two drugs were different from single treatments. The data indicated that both cells were more sensitive to combination treatment (P<0.05) than to single treatments with differences in apoptotic percentage between LNCaP and PC-3 cells (P<0.05). The ratio of combined-treated cells with apoptotic morphology increased dramatically over time and reached about 61.9 ± 1.69 and 47.05 ± 0.34% in treated LNCaP and PC-3 cells respectively after 48 h of treatment (P<0.05) compared to controls (Figure 2B), indicating a potential synergism between paclitaxel and noscapine. In addition, AO/EB staining revealed an increased number of apoptotic cells in LNCaP cells (Figure 2A) compared to PC-3 cells (Figure 2B).
Effect of paclitaxel and noscapine on apoptotic genes expression in LNCaP and PC-3 cells
The results of this study showed that both of 50 µM noscapine or 50 nM paclitaxel and their combination treatments decreased expression of anti-apoptotic molecule Bcl-2 and increased expression of pro-apoptotic molecule Bax in both LNCaP and PC-3 cells after 48 h. Incubation of LNCaP and PC-3 cells with the combination of paclitaxel and noscapine showed significant decrease in Bcl-2 mRNA expression to 0.26 ± 0.01 and 0.28 ± 0.06 (P<0.001) and showed 2.09 ± 0.06 and 1.54 ± 0.05 fold increased in Bax mRNA expression respectively which were significantly different compared to that seen in control groups and treatment with paclitaxel and noscapine alone (P<0.001) (Figure 3A, B). A significant increase in Bax to Bcl-2 ratio of 8.1 ± 0.25 and 4.99 ± 0.5 were observed in LNCaP and PC-3 cells with combined treated of paclitaxel and noscapine respectively (P<0.001) (Figure 3B). However, in LNCaP cells, the lower Bcl-2 and higher Bax and Bax to Bcl-2 ratio mRNA levels were observed after 48 h of treatment compared to PC-3 cells (P<0.001) (Figure 3B)
AR and PSA expression
Our results demonstrated that paclitaxel, noscapine, and their combination inhibited AR and AR-regulated gene PSA expression in LNCaP cells in-vitro. The levels of AR mRNA expression were considerably reduced in combined-treated group compared to the control (P<0.001) (Figure 4A, B). The mRNA AR levels in control, 50 µM noscapine, 50 nM paclitaxel and combination treated groups were 1.54 ± 0.23, 0.88 ± 0.02, 0.81 ± 0.01 and 0.31 ± 0.01 while the mRNA PSA levels were 1.09 ± 0.09, 0.68 ± 0.8, 0.65 ± 0.02 and 0.31 ± 0.02 respectively (P<0.05) (Figure 4B). These results demonstrated that paclitaxel, noscapine, and their combination inhibited LNCaP cells growth probably by a decrease in AR and PSA mRNA expression.
Discussion
In the present study, the synergistic in-vitro effect of paclitaxel and noscapine on two human prostate cancer cell lines, LNCaP, and PC-3 was evaluated and MTT assay indicated that paclitaxel, noscapine and their combination induced dose-and time-dependent inhibitory effect on LNCaP and PC-3 cells. However, both cell types were significantly more sensitive to combination treatments with paclitaxel and noscapine than single treatments, thus confirming the potential beneficial synergism between two reagents, paclitaxel and noscapine. To our knowledge, this is the first study that demonstrates effectiveness of noscapine in combination with paclitaxel against prostate cancer cells.
According to MTT results, LNCaP cells were more sensitive for either paclitaxel or noscapine and their combination than PC-3 cells. The different response between two cell lines may be due to the involvement of androgen pathway. The taxoid, docetaxel (taxotere) that has a mechanism of action similar to paclitaxel (taxol) regulated many genes including microtubule, apoptosis, and cell cycle-related genes in prostate cancer cell lines, LNCaP and PC-3 cells (3). Also, previous study demonstrated that noscapine is effective in reducing primary tumour growth and lymphatic metastasis of PC-3 human prostate cancer cells in immunodeficient nude mice (26).
In particular, results of a study by Landen et al. demonstrated a clear antitumor advantage in murine melanoma B16LS9 cells and model of established subcutaneous melanoma, receiving noscapine or paclitaxel and the noscapine and paclitaxel combination group compared with untreated animals(15) but the cell lines used were different than in our study.
To study the possible mechanism involved in the anticancer activity of paclitaxel and noscapine combination, induction of apoptosis in LNCaP and PC-3 cells was evaluated. Our results indicated that apoptosis is an important pathway associated with the anticancer activity of paclitaxel and noscapine. According to results obtained using AO/EB staining, pacliaxel and noscapine combination treatments showed significant induction of apoptosis in two cell lines in a synergistic manner in compared to untreated cells and single drug treatments. Other studies showed that paclitaxel-induced programmed cell death (8). Our results were consistent with previous study that illustrated treatment of PC-3 cells with paclitaxel resulting in a dose-dependent inhibition of cell viability and the occurrence of DNA laddering and apoptotic cell death (27).
Associated with the antitumor activity of these compounds, studies with noscapine and cisplatin combination also showed that their anticancer activity was mediated by induction of apoptosis via intrinsic and extrinsic pathways and inhibition of survival proteins in H 460 lung tumors (28) thus confirming that apoptosis is an important pathway associated with the anticancer activity of these compounds. Also, induction of apoptosis and expression of cleaved caspase-3 was significantly induced in-vivo by combination treatment compared to noscapine or doxorubicin alone (29). To elucidate the underlying activity mechanism of paclitaxel or noscapine and their combination, we have evaluated the expression of apoptosis-related genes. We could detect differences in expression of Bax and Bcl-2 in various treatment groups. These data suggested that single and combination drug treatments induced apoptosis by down regulation of Bcl-2 and up regulation of Bax in both of LNCaP and PC-3 cells, while treatments in a synergistic manner were more effective.
It has been showed that low doses of paclitaxel enhanced Bcl-2 phosphorylation and led to its degradation and increasing Bax level and induced changes characteristic to apoptosis in human anaplastic cells in thyroid cancer cells (30). Previous reports have indicated that paclitaxel also phosphorylates Bcl-2 to eliminate its anti-apoptotic effect, which accelerates the release of cytochrome C from mitochondria into the cytosol (31, 32).
Liu et al. demonstrated that noscapine increased pro-apototic Bax and decreased anti-apoptotic Bcl-2 proteins that suggested involvement of mitochondrial pathway (33). The present study is therefore in agreement with other studies that demonstrated noscapine alone and combination with doxorubicin induced Bax or decreased Bcl-2 proteins that suggested involvement of mitochondrial pathway and confirmed that apoptosis is an importantpathway (29).
However, in this study mRNA expression level of apoptosis-related genes in LNCaP cells was higher than PC-3 cells in both combination and single treatments that showed LNCaP is more sensitive to treatment than PC-3 in both combination and single treatments.
Impairing AR activity is a targeting for taxol-based chemotherapy during prostate cancer progression (34). In the present study, we reported that combination of microtubule-targeting chemotherapeutic agent’s paclitaxel and noscapine could interfere with AR activity and inhibited LNCaP cells proliferation accompanied by a reduction of AR mRNA expression. These findings suggest that the effects of these drugs may be mediated, at least in part, by inhibition of the AR function, and AR signaling pathway implicated as a therapeutic target.
These observations were in conformity with the results of the previous studies that demonstrated AR plays an important role not only in maintaining the function of the prostate, but also in promoting the development of androgen-dependent and androgen-independent prostate cancers (35, 36). In prostate cancer a preferential expression of membrane ARs has been detected (37) compared with noncancerous cells, correlating to the Gleason’s grade (38), and therefore directly proportional to the aggressiveness of the tumor.
Also we found that the expression of PSA, a well-known AR target gene, is also decreased by paclitaxel, noscapine, and their combination in LNCaP cells. In agreement with our results, two published reports have shown that in advanced, refractory prostate cancer, both docetaxel and paclitaxel improve survival, reduce pain, and decrease expression of AR levels and PSA expression (6, 39) , although with significant side effect (40).
Conclusions
The present in-vitro study indicates that noscapine and paclitaxel combination treatment is effective against LNCaP and PC-3 cells by induction of apoptosis therefore, promising a novel therapeutic strategy to improve the treatment efficiency of prostate cancer therapy.
Acknowledgements
References
-
1.
Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the surveillance, epidemiology, and end results (SEER) Program. Oncologist. 2007;12:20-37. [PubMed ID: 17227898].
-
2.
Khan MA, Carducci MA, Partin AW. The evolving role of docetaxel in the management of androgen independent prostate cancer. J. Urol. 2003;170:1709-16. [PubMed ID: 14532760].
-
3.
Li Y, Li X, Hussain M, Sarkar FH. Regulation of microtubule, apoptosis, and cell cycle-related genes by taxotere in prostate cancer cells analyzed by microarray. Neoplasia. 2004;6:15867.
-
4.
Wani MC, Taylor HL, Wall ME. Plant antitumor agents. VI the isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc. 1971;93:2325-7. [PubMed ID: 5553076].
-
5.
Vokes EE, Stenson K, Rosen FR, Kies MS, Rademaker AW, Witt ME, Brockstein BE, List MA, Fung BB, Portugal L, Mittal BB, Pelzer H, Weichselbaum RR, Haraf DJ. Weekly arboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil and hydroxyurea chemoradio therapy: curative and organ-preserving therapy for advanced head and neck cancer. J. Clin. Oncol. 2003;21:320-6. [PubMed ID: 12525525].
-
6.
Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA. TAX 327 Investigators. Docetaxel plus prednisone or mitoxantroneplus prednisone for advanced prostate cancer. N. Engl. J. Med. 2004;351:1502-12. [PubMed ID: 15470213].
-
7.
Roth AD, Ajani J. Docetaxel-based chemotherapy in the treatment of gastric cancer. Ann. Oncol. 2003;14:41-4.
-
8.
Wang TH, Wang HS, Soong YK. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer. 2000;88:2619-28. [PubMed ID: 10861441].
-
9.
Sadeghi-aliabadi H, Emami SA, Saeidi M, Jafarian A. Cytotoxic effects of the extracts of Iranian Taxus baccata and Cupressus horizentalis on cancer cells. Iran. J. Pharm. Res. 2003;2:107-10.
-
10.
Dumontet C, Sikic BI. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J. Clin. Oncol. 1999;17:1061-70. [PubMed ID: 10071301].
-
11.
Xiao H, Verdier-Pinard P, Fernandez-Fuentes N, Burd B, Angeletti R. Insights into the mechanism of microtubule stabilization by Taxol. Proc. Natl. Aca. Sci. USA. 2006;103:10166-73.
-
12.
Markman M. Managing taxane toxicities. Support Care Cancer. 2003;11:144-147. [PubMed ID: 12618923].
-
13.
Patel N, Chatterjee SK, Vrbanac V, Chung I, Mu CJ, Olsen RR, Waghorne C, Zetter BR. Rescue of paclitaxel sensitivity by repression of prohibitin1in drug-resistant cancer cells. PNAS. 2010;107:2503-8. [PubMed ID: 20133800].
-
14.
Ye K, Ke Y, Keshava N, Shanks J, Kapp JA. Opium alkaloid noscapine is an antitumor agent that arrests metaphase and induces apoptosis in dividing cells. Proc. Natl.Acad. Sci. USA. 1998;95:1601-6. [PubMed ID: 9465062].
-
15.
Landen JW, Lang R, McMahon SJ, Rusan NM, Yvon AM, Adams AW, Sorcinelli MD, Campbell R, Bonaccorsi P, Ansel JC, Archer DR, Wadsworth P, Armstrong CA, Joshi HC. Noscapine alters microtubule dynamics in living cells and inhibits the progression of melanoma. Cancer Res. 2002;62:4109-14. [PubMed ID: 12124349].
-
16.
Khazaei MR, Rashidi Z, Chobsaz F, Khazaei M. Apoptosis induction of human endometriotic epithelial and stromal cells by noscapine. Iran. J. Basic Med. Sci. 2016;19:940-5. [PubMed ID: 27803780].
-
17.
Zhou J, Gupta K, Yao J, Ye K, Panda D, Giannakakou P, Joshi HC. Paclitaxel-resistant human ovarian cancer cells undergo c-Jun NH2-terminal kinase-mediated apoptosis in response to noscapine. J. Biol. Chem. 2002;277:39777-85. [PubMed ID: 12183452].
-
18.
Landen JW, Hau V, Wang M, Davis T, Ciliax B. Noscapine crosses the blood-brain barrier and inhibits glioblastoma growth. Clin.Cancer Res. 2004;10:5187-201. [PubMed ID: 15297423].
-
19.
Aneja R, Zhou J, Vangapandu SN, Zhou B, Chandra R. Drug-resistant T-lymphoid tumors undergo apoptosis selectively in response to an antimicrotubule agent, EM011. Blood. 2006;107:2486-92. [PubMed ID: 16282340].
-
20.
Heidari N, Goliaei B, Moghaddam PR, Rahbar-Roshandel N, Mahmoudian M. Apoptotic pathway induced by noscapine in human myelogenous leukemic cells. Anticancer Drugs. 2007;18:1139-47. [PubMed ID: 17893514].
-
21.
Jackson T, Chougule MB, Ichite N, Patlolla RR, Singh M. Antitumor activity of noscapine in human non-small cell lung cancer xenograft model. Cancer Chemother.Pharma. 2008;63:117-26.
-
22.
Kumi-Diaka J. Chemosensitivity of human prostate cancer cells PC3 and LNCaP to genistein isoflavone and –lapachone. Biol. Cell. 2002;94:37-44. [PubMed ID: 12000145].
-
23.
Pazhouhi M, Sariri R, Rabzia A, Khazaei M. Thymoquinone synergistically potentiates temozolomide cytotoxicity through the inhibition of autophagy in U87MG cell line. Iran. J. Basic Med. Sci. 2016;19:890-8. [PubMed ID: 27746872].
-
24.
Khazaei M, Pazhouhi M. Improved Temozolomide-Mediated Apoptotic Cell Death in U87MG by Thymoquinone. Cancer Investigation. 2017;35:225-36. [PubMed ID: 28355088].
-
25.
Baskić D, Popović S, Ristić P, Arsenijević NN. Analysis of cycloheximide-induced apoptosis in human leukocytes: Fluorescence microscopy using annexin V/propidium iodide versus acridin orange/ethidium bromide. Cell Biol. Int. 2006;30:924-32. [PubMed ID: 16895761].
-
26.
Andriole GL. Overview of pivotal studies for prostate cancer risk reduction, past and present. Urology. 2009;73:36-43.
-
27.
Danesi R, Figg WD, Reed E, Myers CE. Paclitaxel (taxol) inhibits protein isoprenylation and induces apoptosis in PC-3 human prostate cancer cells. Mol. Pharma. 1995;47:1106-11.
-
28.
Chougule MB, Patel AR, Sachdeva P, Jackson T, Singh M. Anticancer activity of noscapine, an opioid alkalid in combination with cisplatin in human non-small cell lung cancer. Mol. Cancer Ther. 2010;71:271-82.
-
29.
Chougule MB, Patel AR, Jackson T, Singh M. Antitumor activity of noscapine in combination with doxorubicin in triple negative breast cancer. PLOS ONE. 2011;6:1-12.
-
30.
Pushkarev VM, Starenki DV, Saenko VA, Namba H, Kurebayashi J, Tronko MD, Yamashita S. Molecular mechanisms of the effects of low concentrations of taxol in anaplastic thyroid cancer cells. Endocrinology. 2004;145:3143-52. [PubMed ID: 15044368].
-
31.
Leung SY, Jackson J, Miyake H, Burt H, Gleave ME. Polymeric micellar paclitaxel phos-phorylates Bcl-2 and induces apoptotic regression of androgen-independent LNCaP prostate tumors. Prostate. 2000;44:156-63. [PubMed ID: 10881025].
-
32.
Figueroa-Masot XA, Hetman M, Higgins MJ, Kokot N, Xia Z. Taxol induces apoptosis in cortical neurons by a mechanism independent of Bcl-2 phosphorylation. J. Neurosci. 2001;21:4657-67. [PubMed ID: 11425893].
-
33.
Liu M, Luo XJ, Liao F, Lei XF, Dong WG. Noscapine induces mitochondria-mediated apoptosis in gastric cancer cells in-vitro and in-vivo. Cancer Chemo.Pharma. 2010;70:3259-68.
-
34.
Zhu ML, Horbinski CM, Garzotto M, Qian DZ, Beer TM, Natasha K. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res. 2010;70:7992-8002. [PubMed ID: 20807808].
-
35.
Grossmann ME, Huang H, Tindall DJ. Androgen receptor signaling in androgen-refractory prostate cancer. J. Nation. Cancer Institute. 2001;93:1687-97.
-
36.
Lee SO, Yeon Chun J, Nadiminty N, Trump DL, Ip C, Dong Y, Gao AC. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA). The Prostate. 2006;66:1070-5. [PubMed ID: 16637076].
-
37.
Stathopoulos EN, Dambaki C, Kampa M, Theodoropoulos PA, Anezini P, Delakas D, Delides1 GS, Castanas E. Membrane androgen binding sites are preferentially expressed in human prostate carcinoma cells. BMC Clin. Pathol. 2003;3:1-9. [PubMed ID: 12588669].
-
38.
Dambaki C, Kogia Ch, Kampa M, Darivianaki K, Nomikos M, Anezinis P, Theodoropoulos PA, Castanas E, Stathopoulos EN. Membrane testosterone binding sites in prostate carcinoma as a potential new marker and therapeutic target: study in paraffin tissue sections. BMC Cancer. 2005;5:1-9. [PubMed ID: 15631637].
-
39.
Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 2004;351:1513-20. [PubMed ID: 15470214].
-
40.
Gan L, Chen S, Wang Y. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. Cancer Res. 2009;69:8386-94. [PubMed ID: 19826044].